Logo image of CCXI

CHEMOCENTRYX INC (CCXI) Stock Price, Quote, News and Overview

NASDAQ:CCXI - Nasdaq - US16383L1061 - Common Stock - Currency: USD

51.99  +0.03 (+0.06%)

After market: 51.99 0 (0%)

CCXI Quote, Performance and Key Statistics

CHEMOCENTRYX INC

NASDAQ:CCXI (10/19/2022, 8:04:24 PM)

After market: 51.99 0 (0%)

51.99

+0.03 (+0.06%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High52
52 Week Low14.95
Market Cap3.71B
Shares71.36M
Float67.40M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)11-08 2022-11-08/amc
IPO02-08 2012-02-08


CCXI short term performance overview.The bars show the price performance of CCXI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

CCXI long term performance overview.The bars show the price performance of CCXI in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of CCXI is 51.99 USD. In the past month the price increased by 0.37%. In the past year, price increased by 50.39%.

CHEMOCENTRYX INC / CCXI Daily stock chart

CCXI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About CCXI

Company Profile

CCXI logo image ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. The company is headquartered in San Carlos, California and currently employs 178 full-time employees. The company went IPO on 2012-02-08. The firm is targeting the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. Its development pipelines include TAVNEOS and Immuno-Oncology. TAVNEOS is for the treatment of severe hidradenitis suppurativa (HS) and seeks to advance TAVNEOS into Phase III clinical development for the treatment of severe HS. The firm's CCX559 is orally-administered investigational inhibitor for programmed death protein 1/programmed death-ligand 1 (PD-1/PD-L1), which is developing for the treatment of various cancers. The company markets TAVNEOS (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis.

Company Info

CHEMOCENTRYX INC

835 Industrial Road, Suite 600

San Carlos CALIFORNIA 94043 US

CEO: Thomas J. Schall

Employees: 178

Company Website: https://www.chemocentryx.com/

Phone: 16502102900.0

CHEMOCENTRYX INC / CCXI FAQ

What is the stock price of CHEMOCENTRYX INC today?

The current stock price of CCXI is 51.99 USD. The price increased by 0.06% in the last trading session.


What is the ticker symbol for CHEMOCENTRYX INC stock?

The exchange symbol of CHEMOCENTRYX INC is CCXI and it is listed on the Nasdaq exchange.


On which exchange is CCXI stock listed?

CCXI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CHEMOCENTRYX INC stock?

13 analysts have analysed CCXI and the average price target is 53.04 USD. This implies a price increase of 2.02% is expected in the next year compared to the current price of 51.99. Check the CHEMOCENTRYX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CHEMOCENTRYX INC worth?

CHEMOCENTRYX INC (CCXI) has a market capitalization of 3.71B USD. This makes CCXI a Mid Cap stock.


How many employees does CHEMOCENTRYX INC have?

CHEMOCENTRYX INC (CCXI) currently has 178 employees.


What are the support and resistance levels for CHEMOCENTRYX INC (CCXI) stock?

CHEMOCENTRYX INC (CCXI) has a support level at 51.98 and a resistance level at 52. Check the full technical report for a detailed analysis of CCXI support and resistance levels.


Is CHEMOCENTRYX INC (CCXI) expected to grow?

The Revenue of CHEMOCENTRYX INC (CCXI) is expected to grow by 117.77% in the next year. Check the estimates tab for more information on the CCXI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CHEMOCENTRYX INC (CCXI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CHEMOCENTRYX INC (CCXI) stock pay dividends?

CCXI does not pay a dividend.


When does CHEMOCENTRYX INC (CCXI) report earnings?

CHEMOCENTRYX INC (CCXI) will report earnings on 2022-11-08, after the market close.


What is the Price/Earnings (PE) ratio of CHEMOCENTRYX INC (CCXI)?

CHEMOCENTRYX INC (CCXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).


CCXI Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CCXI. When comparing the yearly performance of all stocks, CCXI is one of the better performing stocks in the market, outperforming 99.5% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CCXI Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to CCXI. CCXI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CCXI Financial Highlights

Over the last trailing twelve months CCXI reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -6.78% compared to the year before.


Industry RankSector Rank
PM (TTM) -357.01%
ROA -31.74%
ROE N/A
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%21.43%
Sales Q2Q%548.81%
EPS 1Y (TTM)-6.78%
Revenue 1Y (TTM)72.49%

CCXI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 52% to CCXI. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 9.69% and a revenue growth 117.77% for CCXI


Ownership
Inst Owners0%
Ins Owners0.37%
Short Float %N/A
Short RatioN/A
Analysts
Analysts52.31
Price Target53.04 (2.02%)
EPS Next Y9.69%
Revenue Next Year117.77%